LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
$2,45
Prix · Aoû 19, 2026
Données fondamentales au Aoû 6, 2026
Fourchette 52 semaines
$1–$3
86% of range
Note des analystes
BUY
11 analysts
Objectif de cours
$4
+58% upside
P/E (TTM)
-17.5
ROE
-39.7%
Marge nette
-101.1%
À propos de Lexicon Pharmaceuticals, Inc. - Common Stock Présentation de l'entreprise depuis Wikipedia
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Lire la suite
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of diffrent compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
Source : Wikipedia (Anglais), CC BY-SA 4.0 · Voir sur Wikipedia ↗
LXRX Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$2.44
Capitalisation Boursière
$894M
P/E (TTM)
-17.5
BPA (TTM)
$-0.14
Revenus (TTM)
$50M
Rendement div.
—
ROE
-39.7%
Dette/Capitaux propres
0.5
Fourchette 52 semaines
$1 – $3
LXRX Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$50M
2016-12-31
→
2025-12-31
BPA
$-0.14
2017-12-31
→
2025-12-31
Flux de trésorerie libre
$-68M
2016-12-31
→
2025-12-31
Marges
-101.1%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
LXRX
Médiane des pairs
P/E (TTM)
-17.5
29.9
P/S (TTM)
18.0
14.4
P/B
8.3
4.4
EV / EBITDA
-17.6
—
Price / FCF (Cours / FCF)
-13.2
—
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
LXRX
Médiane des pairs
Operating Margin (Marge d'exploitation)
-98.2%
—
Net Profit Margin (Marge nette)
-101.1%
0.70%
ROA
-20.8%
-0.55%
ROE
-39.7%
-2.5%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
LXRX
Médiane des pairs
Debt / Equity (Dette / Capitaux propres)
0.5
—
Current Ratio (Ratio de liquidité)
4.9
3.9
Quick Ratio (Ratio de liquidité réduite)
4.7
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
LXRX
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
60.2%
—
Revenue CAGR 3Y (CAGR du chiffre d'affaires 3 ans)
610.2%
—
Revenue CAGR 5Y (CAGR du chiffre d'affaires 5 ans)
15.7%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
LXRX
Médiane des pairs
LXRX Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
11 analystes
- Achat fort 3 27,3%
- Achat 5 45,5%
- Conserver 3 27,3%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
5 analystes · 2026-08-19
Médiane
$3.10
Moyenne
$3.86
Maintenant
$2.44
Bas
$2.00
Haut
$6.00
Objectif médian
$3.10
+26,8%
Objectif moyen
$3.86
+57,7%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.03%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 30 juin 2026 | $-0.07 | $-0.05 | -0.02% |
| 31 mars 2026 | $0.00 | $-0.04 | 0.04% |
| 31 décembre 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 septembre 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 juin 2025 | $0.01 | $-0.08 | 0.09% |
| 31 mars 2025 | $-0.07 | $-0.10 | 0.03% |
Comparaison des pairs (sous-secteur GICS) Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | — |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
| EYPT | $1.51B | -5.8 | -27.5% | -739.4% | -84.0% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | — |
| SGP | — | — | — | — | 50.0% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 16
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
Bilan 30
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
Flux de trésorerie 17
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
Liquidité et Solvabilité 5
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
Efficacité 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
Taux de croissance 3
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 14
| Métrique | Tendance | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
Compte de résultat 14
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | -725,713,000 | 363,399,000 | 363,294,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | -307,937,000 | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | -725,989,000 | 363,399,000 | 363,570,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | 7,749,000 | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | $-26M | · | $-64M | $-55M | $-45M | · | $-50M | $-44M | $-31M | · | $-23M |
Bilan 28
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | $101M | · | $100M | $99M | $100M | · | $99M | $99M | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
Flux de trésorerie 14
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | $-22M | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
Rentabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | -2034.8% | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | -13955.8% | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | -2004.4% | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | -14165.3% | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | -2020.8% | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | -13955.8% | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | -7.1% | · | -21.7% | -15.5% | -16.7% | · | -21.6% | -20.9% | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | -12.3% | · | -40.8% | -25.1% | -25.7% | · | -35.6% | -34.9% | -35.3% | · | -16.7% |
Liquidité et Solvabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | 2.2 | · | 7.5 | 11.5 | 15.6 | · | 6.9 | 10.1 | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | 2.2 | · | 7.2 | 11.2 | 15.3 | · | 6.8 | 9.9 | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.8 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.5 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | -22.6 | -17.1 | · | -26.7 |
Efficacité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | 0.4 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | 0.1 | · | 1.1 | 1.0 | 1.3 | · | 0.9 | 0.9 | · | · | · |
Valorisation (TTM) 12
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65M | $65M | · | $46M | $34M | $6M | · | $5M | $3M | $2M | · | $542.0K | $415.0K | · | · | · | |
| Net Income TTM | $-42M | $-36M | · | $-100M | $-140M | $-192M | · | $-217M | $-197M | $-176M | · | $-151M | $-125M | $-103M | · | $-95M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -24.0 | -15.6 | · | -4.8 | -2.3 | -0.7 | · | -2.1 | -2.1 | -3.0 | · | -1.5 | · | · | · | · | |
| P/S | 16.5 | 10.2 | · | 10.7 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -35.2 | -613.0 | · | -35.6 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 14.4 | 8.3 | · | 9.4 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.2% | -6.4% | · | -20.7% | -43.2% | -134.8% | · | -48.4% | -47.6% | -33.3% | · | -67.0% | · | · | · | · |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $50M | $31M | $1M | $139.0K | $298.0K |
| Marge d'exploitation % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| Résultat net | $-50M | $-200M | $-177M | $-102M | $-88M |
| BPA dilué | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dette / Capitaux propres | 0.5 | 0.7 | 1.1 | — | 0.0 |
| Ratio de liquidité | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| Ratio de liquidité réduite | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-68M | $-180M | $-162M | $-90M | $-88M |
Dernières actualités Actualités récentes mentionnant cette entreprise
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 169 déclarants · $760.9M total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 48 (+19 vs T. préc.) | 26 (+13 vs T. préc.) | 34 (-11 vs T. préc.) | 37 (+17 vs T. préc.) | +36.5M |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| Artal Group S.A. | $420 374 549 | 175 156 062 | 55,25% | Actions |
| Siren, L.L.C. | $106 328 443 | 44 303 518 | 13,97% | Actions |
| FMR LLC | $65 057 059 | 27 107 108 | 8,55% | Actions |
| Sessa Capital IM, L.P. | $45 506 006 | 18 960 836 | 5,98% | Actions |
| VANGUARD CAPITAL MANAGEMENT LLC | $23 762 899 | 9 901 208 | 3,12% | Actions |
| Point72 Asset Management, L.P. | $19 803 180 | 8 251 325 | 2,60% | Actions |
| GEODE CAPITAL MANAGEMENT, LLC | $12 946 507 | 5 393 025 | 1,70% | Actions |
| STATE STREET CORP | $11 802 646 | 4 917 769 | 1,55% | Actions |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5 658 598 | 2 357 749 | 0,74% | Actions |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4 696 260 | 1 956 775 | 0,62% | Actions |
| VANGUARD FIDUCIARY TRUST CO | $3 922 970 | 1 634 571 | 0,52% | Actions |
| CIBC Private Wealth Group LLC | $3 240 347 | 2 400 257 | 0,43% | Actions |
| Ishara Investments LP | $3 050 400 | 1 271 000 | 0,40% | Actions |
| MILLENNIUM MANAGEMENT LLC | $2 722 150 | 1 134 229 | 0,36% | Actions |
| RENAISSANCE TECHNOLOGIES LLC | $2 704 800 | 1 127 000 | 0,36% | Actions |
| MACKENZIE FINANCIAL CORP | $2 312 050 | 963 354 | 0,30% | Actions |
| ADAR1 Capital Management, LLC | $1 800 000 | 750 000 | 0,24% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 604 400 | 668 500 | 0,21% | Option d'achat |
| TWO SIGMA INVESTMENTS, LP | $1 544 266 | 643 444 | 0,20% | Actions |
| JANE STREET GROUP, LLC | $1 398 960 | 582 900 | 0,18% | Option d'achat |
| CITADEL ADVISORS LLC | $1 348 733 | 561 972 | 0,18% | Actions |
| VANGUARD GROUP INC | $1 277 587 | 1 110 945 | 0,17% | Actions |
| Compagnie Lombard Odier SCmA | $1 152 000 | 480 000 | 0,15% | Actions |
| BARCLAYS PLC | $890 636 | 371 098 | 0,12% | Actions |
| CITADEL ADVISORS LLC | $886 320 | 369 300 | 0,12% | Option d'achat |
| XTX Topco Ltd | $858 905 | 357 877 | 0,11% | Actions |
| GOLDMAN SACHS GROUP INC | $725 810 | 302 421 | 0,10% | Actions |
| CANADA PENSION PLAN INVESTMENT BOARD | $618 960 | 257 900 | 0,08% | Actions |
| RHUMBLINE ADVISERS | $616 523 | 256 885 | 0,08% | Actions |
| WELLS FARGO & COMPANY/MN | $544 865 | 227 027 | 0,07% | Actions |
| GROUP ONE TRADING LLC | $420 031 | 175 013 | 0,06% | Actions |
| Virtus Investment Advisers, LLC | $408 996 | 170 415 | 0,05% | Actions |
| Headlands Technologies LLC | $401 275 | 167 198 | 0,05% | Actions |
| Ikarian Capital, LLC | $395 218 | 164 674 | 0,05% | Actions |
| CITIGROUP INC | $386 021 | 160 842 | 0,05% | Actions |
| Quarry LP | $374 846 | 156 186 | 0,05% | Actions |
| MetLife Investment Management, LLC | $351 384 | 146 410 | 0,05% | Actions |
| Bank of New York Mellon Corp | $345 307 | 143 878 | 0,05% | Actions |
| BANK OF AMERICA CORP /DE/ | $344 321 | 143 467 | 0,05% | Actions |
| PANAGORA ASSET MANAGEMENT INC | $316 901 | 132 042 | 0,04% | Actions |
| State of Wyoming | $285 816 | 119 090 | 0,04% | Actions |
| BlackRock, Inc. | $284 436 | 118 515 | 0,04% | Actions |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $273 874 | 114 114 | 0,04% | Actions |
| Cornerstone Investment Partners, LLC | $272 974 | 113 739 | 0,04% | Actions |
| Invesco Ltd. | $238 190 | 99 246 | 0,03% | Actions |
| ALGERT GLOBAL LLC | $221 160 | 92 150 | 0,03% | Actions |
| TWO SIGMA ADVISERS, LP | $208 124 | 180 977 | 0,03% | Actions |
| BANK OF NOVA SCOTIA | $207 857 | 86 607 | 0,03% | Actions |
| LPL Financial LLC | $203 799 | 84 916 | 0,03% | Actions |
| Vanguard Global Advisers, LLC | $187 070 | 77 946 | 0,02% | Actions |
| AQR CAPITAL MANAGEMENT LLC | $180 101 | 75 042 | 0,02% | Actions |
| Police & Firemen's Retirement System of New Jersey | $176 165 | 73 402 | 0,02% | Actions |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | $171 426 | 71 427 | 0,02% | Actions |
| PRUDENTIAL FINANCIAL INC | $171 228 | 71 345 | 0,02% | Actions |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $167 393 | 69 747 | 0,02% | Actions |
| NEW YORK STATE COMMON RETIREMENT FUND | $164 160 | 68 400 | 0,02% | Actions |
| TWO SIGMA SECURITIES, LLC | $159 300 | 66 375 | 0,02% | Actions |
| SEI INVESTMENTS CO | $153 449 | 63 937 | 0,02% | Actions |
| Nuveen, LLC | $153 449 | 63 937 | 0,02% | Actions |
| Straight Path Wealth Management | $150 398 | 62 666 | 0,02% | Actions |
| WELLINGTON MANAGEMENT GROUP LLP | $144 000 | 60 000 | 0,02% | Actions |
| R Squared Ltd | $131 964 | 54 985 | 0,02% | Actions |
| Vanguard Personalized Indexing Management, LLC | $130 402 | 54 334 | 0,02% | Actions |
| Fortis Group Advisors, LLC | $120 000 | 50 000 | 0,02% | Actions |
| Schonfeld Strategic Advisors LLC | $118 642 | 49 435 | 0,02% | Actions |
| SCOTIA CAPITAL INC. | $117 291 | 48 871 | 0,02% | Actions |
| PROFUND ADVISORS LLC | $116 606 | 48 586 | 0,02% | Actions |
| VOYA INVESTMENT MANAGEMENT LLC | $114 650 | 47 771 | 0,02% | Actions |
| AXQ CAPITAL, LP | $109 745 | 45 727 | 0,01% | Actions |
| BOOTHBAY FUND MANAGEMENT, LLC | $106 356 | 44 315 | 0,01% | Actions |
| ALLIANCEBERNSTEIN L.P. | $105 768 | 67 800 | 0,01% | Actions |
| WINTON GROUP Ltd | $103 680 | 43 200 | 0,01% | Actions |
| INTECH INVESTMENT MANAGEMENT LLC | $101 978 | 42 491 | 0,01% | Actions |
| LMR Partners LLP | $98 618 | 41 091 | 0,01% | Actions |
| BANK OF MONTREAL /CAN/ | $96 000 | 40 000 | 0,01% | Actions |
| NORTHERN TRUST CORP | $93 794 | 39 081 | 0,01% | Actions |
| BNP PARIBAS FINANCIAL MARKETS | $90 672 | 37 780 | 0,01% | Actions |
| Cubist Systematic Strategies, LLC | $85 704 | 63 484 | 0,01% | Actions |
| Rafferty Asset Management, LLC | $81 816 | 34 090 | 0,01% | Actions |
| ProShare Advisors LLC | $78 212 | 32 588 | 0,01% | Actions |
| Leonteq Securities AG | $72 000 | 30 000 | 0,01% | Actions |
| PINNACLE ASSOCIATES LTD | $69 636 | 29 015 | 0,01% | Actions |
| VICTORY CAPITAL MANAGEMENT INC | $58 135 | 24 223 | 0,01% | Actions |
| Legal & General Group Plc | $58 044 | 24 185 | 0,01% | Actions |
| XPONANCE LLC | $57 031 | 23 763 | 0,01% | Actions |
| Graham Capital Management, L.P. | $56 498 | 23 541 | 0,01% | Actions |
| D. E. Shaw & Co., Inc. | $53 280 | 22 200 | 0,01% | Actions |
| Quadrature Capital Ltd | $52 795 | 21 998 | 0,01% | Actions |
| Invera Wealth Advisors, LLC | $48 000 | 20 000 | 0,01% | Actions |
| DIKER MANAGEMENT LLC | $48 000 | 20 000 | 0,01% | Actions |
| TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | $48 000 | 20 000 | 0,01% | Actions |
| Russell Investments Group, Ltd. | $47 764 | 19 902 | 0,01% | Actions |
| Point72 Asia (Singapore) Pte. Ltd. | $47 282 | 35 024 | 0,01% | Actions |
| Tower Research Capital LLC (TRC) | $46 764 | 19 485 | 0,01% | Actions |
| KWB Wealth | $46 736 | 40 640 | 0,01% | Actions |
| SBI Securities Co., Ltd. | $46 092 | 19 205 | 0,01% | Actions |
| PRINCIPAL FINANCIAL GROUP INC | $45 682 | 19 034 | 0,01% | Actions |
| CREDIT AGRICOLE S A | $45 540 | 18 975 | 0,01% | Actions |
| WOLVERINE TRADING, LLC | $43 785 | 31 500 | 0,01% | Option de vente |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $42 960 | 17 900 | 0,01% | Option de vente |
Initiés de la société 49 initiés · 32 dirigeants · 19 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 février 2026 M | 298 432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 février 2024 M | 1 098 068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 février 2014 M | 1 021 329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 février 2026 M | 105 356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2 juin 2009 A | — | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 7 février 2008 A | 50 200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 8 juillet 2024 A | 324 214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 février 2026 M | 31 264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 février 2026 M | 150 132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 février 2026 M | 277 945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 février 2026 M | 323 430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 février 2026 M | 93 869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 février 2026 M | 428 802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 février 2025 M | 76 368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 février 2025 M | 339 104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 février 2025 A | — | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 février 2024 M | 162 672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 8 février 2024 A | — | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 février 2023 M | 53 136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 mars 2021 M | 71 766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 avril 2020 F | 55 584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 avril 2020 F | 85 719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2 mars 2015 M | 8 235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 février 2014 M | 278 703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 février 2010 A | — | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 février 2010 A | 27 306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 7 février 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 7 février 2008 A | 10 200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 7 février 2008 A | — | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 février 2007 A | — | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 février 2004 M | 15 000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 janvier 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | Administrateur | 3 juin 2026 M | 89 312 | 0 | 0 | $0 |
| Diane E. Sullivan | Administrateur | 3 juin 2026 M | 126 122 | 0 | 0 | $0 |
| Judith L Swain | Administrateur | 3 juin 2026 M | 174 486 | 0 | 0 | $0 |
| Amouyal Philippe | Administrateur | 3 juin 2026 M | 374 486 | 0 | 0 | $0 |
| Sam L Barker | Administrateur | 3 juin 2026 M | 213 771 | 0 | 0 | $0 |
| Christopher J Sobecki | Administrateur | 3 juin 2026 M | 293 177 | 0 | 0 | $0 |
| Raymond Debbane | Administrateur | 3 juin 2026 M | 1 995 498 | 7 | 0 | $723 048 |
| Robert J Lefkowitz MD | Administrateur | 13 mai 2024 A | 48 364 | 0 | 0 | $0 |
| Frank Palantoni | Administrateur | 21 mai 2023 M | 40 332 | 0 | 0 | $0 |
| Alan S Nies | Administrateur | 21 mai 2023 M | 41 046 | 0 | 0 | $0 |
| Invus C.V. | Administrateur | 31 décembre 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | Administrateur | 24 avril 2009 A | — | 0 | 0 | $0 |
| Clayton Stuart Rose | Administrateur | 26 juin 2007 P | 25 000 | 0 | 0 | $0 |
| Barry Mills | Administrateur | 26 avril 2007 A | 25 000 | 0 | 0 | $0 |
| Patricia M Cloherty | Administrateur | 27 avril 2006 A | — | 0 | 0 | $0 |
| Thomas C Caskey | Administrateur | 13 octobre 2005 P | 6 300 | 0 | 0 | $0 |
| Praveen Tyle | — | 28 février 2021 M | 120 791 | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 11 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 dépôts | 8 mai 2026 | 39,40% | Amendement | — | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 dépôts | 9 décembre 2024 | — | Dépôt initial | — | SEC |
| 24 février 2012 | — | Dépôt initial | — | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 décembre 2011 | — | Dépôt initial | — | SEC |
| 14 novembre 2011 | — | Dépôt initial | — | SEC | |
| 15 août 2011 | — | Dépôt initial | — | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 mars 2010 | — | Dépôt initial | Structure du capital | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 dépôts | 5 août 2005 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 8 août 2003 | — | Dépôt initial | — | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 18 juillet 2003 | — | Dépôt initial | Investissement passif | SEC |
| Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée, Personne déclarante non divulguée | 19 mars 2003 | — | Dépôt initial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Détention d'ETF Détenu par 14 ETFs
Le poids reflète uniquement les participations directes en actions (N-PORT) ; les fonds à effet de levier ou basés sur des dérivés peuvent détenir une exposition supplémentaire aux swaps non indiquée.
| Fonds | Poids | Unités | Au | Source |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,56% | 51 356 SH | 8 août 2026 | Quotidien |
| IWC · iShares Trust | 0,13% | 841 693 SH | 8 août 2026 | Quotidien |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 266 401 SH | 8 août 2026 | Quotidien |
| IWO · iShares Trust | 0,04% | 2 223 001 SH | 8 août 2026 | Quotidien |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,03% | 323 271 SH | 8 août 2026 | Quotidien |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1 432 882 SH | 8 août 2026 | Quotidien |
| IWM · iShares Trust | 0,02% | 6 194 737 SH | 8 août 2026 | Quotidien |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2 594 934 SH | 8 août 2026 | Quotidien |
| VHT · VANGUARD WORLD FUND | 0,01% | 637 561 SH | 8 août 2026 | Quotidien |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 1 032 223 NS | 31 mai 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 84 479 SH | 8 août 2026 | Quotidien |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 110 085 NS | 31 mai 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 7 083 651 SH | 8 août 2026 | Quotidien |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 20 905 SH | 8 août 2026 | Quotidien |